Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P
PiLeJe, 37, quai-de-Grenelle, bâtiment Pollux, 75738 Paris cedex 15, France.
Gastroenterol Clin Biol. 2008 Feb;32(2):147-52. doi: 10.1016/j.gcb.2007.06.001. Epub 2008 Mar 4.
The purpose of this study was to evaluate the effects of a probiotic combination on symptoms in patients with irritable bowel syndrome (IBS).
We investigated the efficiency of a probiotic dietary supplement, containing four strains of lactic acid bacteria, on symptoms of IBS. One hundred and sixteen patients with IBS fulfilling the Rome II criteria were randomized in a parallel group, double-blind study to receive a placebo or a probiotic combination (1 x 10(10) cfu once daily) for four weeks. The symptoms that were monitored weekly included discomfort, abdominal pain, and stool frequency and quality. Quality of life was assessed before and at the end of the treatment using the SF36 and FDD-quality-of-life questionnaires.
One hundred subjects completed the study (48 probiotic combination, 52 placebo). The probiotic combination was not superior to the placebo in relieving symptoms of IBS (42.6 versus 42.3% improvement). However, the decrease of abdominal pain between the first and the fourth week of treatment was significantly higher in probiotic treated patients (-41.9 versus -24.2%, P=0.048). Interesting findings from the IBS sub-groups were also observed such as a lower pain score at end point in patients with alternating bowel habits (P=0.023) and an increase of stool frequency in the constipated sub-group from the first week of probiotic treatment (P=0.043).
The probiotic combination was not significantly superior to the placebo in relieving symptoms of IBS. Despite the apparent high placebo response, interesting findings from IBS sub-groups were observed in the field of abdominal pain and stool frequency.
本研究旨在评估益生菌组合对肠易激综合征(IBS)患者症状的影响。
我们调查了一种含有四株乳酸菌的益生菌膳食补充剂对IBS症状的疗效。116例符合罗马II标准的IBS患者被随机分为平行组、双盲研究,接受安慰剂或益生菌组合(每日1次,每次1×10¹⁰ cfu),为期四周。每周监测的症状包括不适、腹痛、大便频率和质量。使用SF36和FDD生活质量问卷在治疗前和治疗结束时评估生活质量。
100名受试者完成了研究(48例接受益生菌组合,52例接受安慰剂)。益生菌组合在缓解IBS症状方面并不优于安慰剂(改善率分别为42.6%和42.3%)。然而,益生菌治疗组患者在治疗第一周和第四周之间腹痛的减轻明显更高(-41.9%对-24.2%,P = 0.048)。在IBS亚组中也观察到了有趣的发现,例如排便习惯交替的患者在终点时疼痛评分较低(P = 0.023),便秘亚组从益生菌治疗第一周起大便频率增加(P = 0.043)。
益生菌组合在缓解IBS症状方面并不显著优于安慰剂。尽管安慰剂反应明显较高,但在腹痛和大便频率方面,IBS亚组仍观察到了有趣的发现。